Management of drug-induced interstitial lung disease in the era of evolving lung cancer therapies: A mini-review
{{output}}
The therapeutic landscape for lung cancer has been transformed by the introduction of molecular targeted therapies, immune checkpoint inhibitors (ICIs), and antibody-drug conjugates (ADCs). However, this expansion of treatment options has been accompanied by a... ...
